Core Insights - Geron Corporation has appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors, enhancing its leadership team with experienced industry veterans [1][2][3] Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on changing the course of blood cancer, with its first-in-class telomerase inhibitor RYTELO (imetelstat) approved in the U.S. and EU for treating certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia [4] - The company is conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis and other hematologic malignancies [4] Leadership Experience - Patricia S. Andrews brings extensive experience, having served in various leadership roles, including CEO of Sumitomo Pharma Oncology and positions at Glenmark Pharmaceuticals and Oncolytics Biotech [2][3] - Constantine Chinoporos has held senior positions in business development and corporate finance at companies like Applied Therapeutics and Albireo Pharmaceuticals, and currently serves as a strategic advisor to Apollo Therapeutics [3] Strategic Focus - The new board members are expected to provide valuable insights as Geron executes its strategic priorities and drives commercial growth for RYTELO [2] - Both Andrews and Chinoporos expressed their commitment to supporting Geron's focused commercial strategy and long-term growth objectives [2][3]

Core Insights - Geron Corporation reported a net product revenue of $48 million for Q4 2025 and $184 million for the full year 2025, indicating a growth in demand for RYTELO [1][5] - The company ended 2025 with approximately $401 million in cash and marketable securities, down from $503 million in 2024 [4][22] - Geron reiterated its financial guidance for 2026, expecting RYTELO net product revenue between $220 million and $240 million, and total operating expenses between $230 million and $240 million [1][14] Financial Performance - Total product revenue for Q4 2025 was $48 million, compared to $47.5 million in Q4 2024, while full-year revenue increased from $76.5 million in 2024 to $183.6 million in 2025 [7][8] - The company reported a net loss of $31.1 million for Q4 2025, compared to a net loss of $25.4 million in Q4 2024, and a total net loss of $85.8 million for the full year 2025, down from $174.6 million in 2024 [5][6] - Total operating expenses for 2025 were $255 million, slightly above the previous year's $250.7 million [9] Operational Highlights - RYTELO demand grew by 9% in Q4 2025 compared to Q3 2025, with an increase of 150 ordering accounts, bringing the total to approximately 1,300 [5] - The company is focusing on driving U.S. commercial growth and exploring international opportunities for RYTELO, supported by FDA approval and scientific evidence [2][22] - Geron is preparing for the IMpactMF interim analysis in relapsed/refractory myelofibrosis and anticipates initial data from real-world experience trials in lower-risk MDS in the second half of 2026 [2] Cost Management - Research and development expenses decreased to $73.7 million in 2025 from $103.7 million in 2024, primarily due to lower clinical trial costs following RYTELO's approval [11] - Selling, general, and administrative expenses increased to $159.3 million in 2025 from $145.7 million in 2024, attributed to higher sales and marketing investments [12] - Restructuring charges of $17 million were incurred in 2025 due to a workforce reduction of approximately one-third of the staff [13]

Core Viewpoint - Geron Corporation is focused on transforming the treatment landscape for blood cancer through its innovative therapies, particularly its first-in-class telomerase inhibitor, RYTELO (imetelstat) [2]. Company Overview - Geron is a commercial-stage biopharmaceutical company dedicated to changing lives by altering the course of blood cancer [2]. - RYTELO (imetelstat) has received approval in the United States and the European Union for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia [2]. - The company is conducting a pivotal Phase 3 clinical trial of imetelstat in patients with JAK-inhibitor resistant/refractory myelofibrosis (R/R MF) and is also exploring its use in other hematologic malignancies [2]. - The mechanism of action involves inhibiting telomerase activity, which is elevated in malignant stem and progenitor cells in the bone marrow, potentially reducing proliferation and inducing death of malignant cells [2]. Investor Engagement - Geron management is scheduled to present at several upcoming investor conferences, including: - TD Cowen 46th Annual Healthcare Conference on March 2 at 1:10 p.m. ET in Boston, MA [3]. - Barclays 28th Annual Global Healthcare Conference on March 10 at 10:30 a.m. ET in Miami, FL [3]. - Leerink Partners Global Healthcare Conference with in-person meetings on March 11 in Miami, FL [3]. - Live and archived audio webcasts of these presentations will be available on Geron's website [1].

Core Viewpoint - Geron Corporation is set to release its fourth quarter and full year 2025 financial results on February 25, 2026, and will host a conference call to discuss these results [1][2]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on changing the course of blood cancer [3]. - The company's first-in-class telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and the European Union for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia [3]. - Geron is conducting a pivotal Phase 3 clinical trial of imetelstat in patients with JAK-inhibitor resistant/refractory myelofibrosis (R/R MF) and is also exploring its use in other hematologic malignancies [3]. - The mechanism of action involves inhibiting telomerase activity, which is elevated in malignant stem and progenitor cells in the bone marrow, potentially reducing proliferation and inducing death of malignant cells [3].

Core Insights - Geron Corporation presented new data at the ASH 2025 Annual Meeting, reinforcing the potential of RYTELO (imetelstat) as a treatment for lower-risk myelodysplastic syndromes (LR-MDS) and myelofibrosis (MF) [1][2][4] Group 1: Clinical Efficacy of Imetelstat - Pooled analyses from the IMerge trial suggest that early treatment-emergent cytopenias may correlate with significant clinical outcomes, including hemoglobin increases and transfusion independence in LR-MDS patients [2][4][6] - The data indicate that patients experiencing ≥75% reductions in neutrophils or ≥50% reductions in platelets during the first two cycles of treatment had greater maximum hemoglobin increases compared to those without such reductions [5][6] - Long-term follow-up from the IMerge trial shows favorable trends in overall survival (OS) and progression-free survival (PFS) for imetelstat-treated patients compared to placebo, with a median follow-up of 45 months [7][8][9] Group 2: Mechanism of Action and Biological Insights - Imetelstat's mechanism involves telomerase inhibition, which is crucial for the uncontrolled cell division seen in LR-MDS, and the treatment has shown potential disease-modifying properties [19][20] - The correlation between early blood count changes and later improvements in hemoglobin provides valuable insights for clinicians regarding the treatment's biological effects [3][6] Group 3: Additional Studies and Future Directions - Ongoing studies, including the IMproveMF trial, are evaluating the safety and efficacy of imetelstat in combination with ruxolitinib for patients with intermediate-2 or high-risk myelofibrosis [13][14] - Preliminary results from the IMpress study indicate that imetelstat has a manageable safety profile in advanced myelodysplastic neoplasms or acute myeloid leukemia patients who are refractory to prior treatments [15][16][17]